source
- Parabilis Medicines charts $413M IPO to back peptide pipelineParabilis Medicines, the peptide biotech led by former Johnson & Johnson R&D head Mathai Mammen, is seeking more than $400 million in its Nasdaq debut. If the drug developer follows through with it…Endpoints · 1mo ago↗ source
- Scientists uncover a new hiding spot for HIVAn Ebola update, Trump to strip job protections of NIH officials, and more health news from Morning RoundsSTAT · 1mo ago↗ source
- ADC Therapeutics' confirmatory data for Zynlonta muddied by death ratesADC Therapeutics’ bid to secure full approval for Zynlonta in relapsed or refractory diffuse large B-cell lymphoma has been complicated by death rates in its confirmatory trial. The company said ...Endpoints · 1mo ago